112 related articles for article (PubMed ID: 1688571)
1. Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy.
Masson H; Popescu I; Strubel D; Cramer H; Kuntzmann F
J Am Geriatr Soc; 1990 Jan; 38(1):19-24. PubMed ID: 1688571
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia.
Jolkkonen J; Soininen H; Halonen T; Ylinen A; Laulumaa V; Laakso M; Riekkinen P
J Neurol Neurosurg Psychiatry; 1986 Dec; 49(12):1374-7. PubMed ID: 2433403
[TBL] [Abstract][Full Text] [Related]
3. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Rinne UK; Marttila R
Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
[TBL] [Abstract][Full Text] [Related]
4. Decreased beta-phenylethylamine in CSF in Parkinson's disease.
Zhou G; Shoji H; Yamada S; Matsuishi T
J Neurol Neurosurg Psychiatry; 1997 Dec; 63(6):754-8. PubMed ID: 9416810
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease and dementia: clinical and neurochemical correlations.
Strittmatter MM; Cramer H
Neuroreport; 1992 May; 3(5):413-6. PubMed ID: 1378766
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.
Strittmatter M; Hamann GF; Strubel D; Cramer H; Schimrigk K
J Neural Transm (Vienna); 1996; 103(5):591-602. PubMed ID: 8811504
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
Korf J; van Praag HM; Schut D; Nienhuis RJ; Lakke JP
Eur Neurol; 1974; 12(5-6):340-50. PubMed ID: 4448192
[No Abstract] [Full Text] [Related]
8. [The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Liu DK
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Apr; 22(2):95-8, 126-7. PubMed ID: 2791764
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrobiopterin and Parkinson's disease.
Dissing IC; Güttler F; Pakkenberg H; Lou H; Gerdes AM; Lykkelund C; Rasmussen V
Acta Neurol Scand; 1989 Jun; 79(6):493-9. PubMed ID: 2476906
[TBL] [Abstract][Full Text] [Related]
10. CSF cyclic nucleotides and somatostatin in Parkinson's disease.
Volicer L; Beal MF; Direnfeld LK; Marquis JK; Albert ML
Neurology; 1986 Jan; 36(1):89-92. PubMed ID: 2867490
[TBL] [Abstract][Full Text] [Related]
11. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H
J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587
[TBL] [Abstract][Full Text] [Related]
12. [Drug-induced dyskinesia during the treatment of Parkinson disease--biochemical studies].
Friedman A
Neurol Neurochir Pol; 1985; 19(5):401-3. PubMed ID: 2421191
[TBL] [Abstract][Full Text] [Related]
13. CSF somatostatin increase in patients with early parkinsonian syndrome.
Espino A; Calopa M; Ambrosio S; Ortolà J; Peres J; Navarro MA
J Neural Transm Park Dis Dement Sect; 1995; 9(2-3):189-96. PubMed ID: 8527003
[TBL] [Abstract][Full Text] [Related]
14. Monoamine metabolites and neuropeptides in patients with Parkinson's disease, Huntington's chorea, Shy-Drager syndrome, and torsion dystonia.
Lindvall B; Olsson JE
Adv Neurol; 1990; 53():117-22. PubMed ID: 1700581
[No Abstract] [Full Text] [Related]
15. Brain dopamine turnover and the relief of parkinsonism.
Rinne UK; Sonninen V; Marttila R
Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients.
Cramer H; Rissler K; Rösler N; Strubel D; Schaudt D; Kuntzmann F
Eur Neurol; 1989; 29(1):1-5. PubMed ID: 2468498
[TBL] [Abstract][Full Text] [Related]
18. [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
Fischer PA; Przuntek H; Majer M; Welzel D
Dtsch Med Wochenschr; 1984 Aug; 109(34):1279-83. PubMed ID: 6381019
[TBL] [Abstract][Full Text] [Related]
19. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Liu DK
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr; 13(4):223-6. PubMed ID: 6790255
[No Abstract] [Full Text] [Related]
20. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Olanow CW; Gauger LL; Cedarbaum JM
Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
